Open AccessTargeted α therapy with 213Bi and 225Ac
Author(s) -
A. Kellerbauer,
Frank Bruchertseifer,
Rikard Malmbeck,
Alfred Morgenstern
Publication year - 2020
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1643/1/012205
Subject(s) - radionuclide , radiation therapy , nuclear medicine , radiochemistry , medicine , radionuclide therapy , medical physics , nuclear physics , chemistry , physics
The molecularly targeted treatment of cancerous tumors by the alpha-emitting radionuclides 213 Bi and 225 Ac has shown remarkable efficacy in clinical trials. Ultimately, this treatment option will be applicable to a wide range of cancers and other diseases, subject to the development of specific radioligands. Currently 225 Ac is mainly being produced from the decay of existing stocks of 229 Th. The expected wider application for radiotherapy will require many orders of magnitude more radionuclide than can currently be produced. Consequently, various alternative production methods are being pursued.